Both UHN start-ups MolecuLight I:X and BresoTec Inc., were recognized for their global impact as diagnostic tools in the Toronto Star. Read the details of how UHN’s cutting-edge technology is changing lives around the world HERE!
Licensing and Commercialization Associate - Toronto, Ontario Please apply on-line at: https://www.recruitingsite.com/csbsites/uhncareers/JobDescription.asp?SiteID=10031&JobNumber=800940 Job Posting #800940 Position: Licensing and Commercialization Associate Site: MaRS – Heritage Building Department: Technology Development & Commercialization (TDC) Reports to: Team Lead, Licensing and Commercialization Salary Range: Commensurate with experience and consistent with UHN Compensation Policy Status: Temporary Full-Time, 1 year contract University Health Network (UHN) is […]
Wednesday, March 08, 2017 We are incredibly proud to announce that two cancer program oncologists and two cancer scientists have received the 2017 Canadian Cancer Society Awards for Excellence announced today. These Awards recognize individuals who have made, and are making, valuable contributions to cancer research and cancer control in Canada. Recipients are leaders […]
University Health Network (UHN) in Toronto, ON has commenced Phase 1 testing of its novel cell and gene therapy for Fabry disease, pioneered within the lab of Dr. Jeffrey Medin (now at the Medical College of Wisconsin). AVROBIO, Inc. is the exclusive licensee for this therapy, and is further developing it worldwide. A leader in […]
Partnership positions Princess Margaret Cancer Centre to provide Canadian perspective on a Network of 21 academic centres from around the world to access and share technology, data and expertise to advance the science of cancer immunotherapy Roche invests up to 100 million Swiss Francs (more than $130 million Canadian dollars) to support basic and clinical research collaborations […]